First Trust NYSE® Arca® Biotechnology Index Fund (FBT)
Investment Objective/Strategy - The First Trust NYSE® Arca® Biotechnology Index Fund is an exchange-traded index fund. The investment objective of the Fund is to replicate as closely as possible, before fees and expenses, the price and yield of the NYSE® Arca Biotechnology Index.
There can be no assurance that the Fund's investment objectives will be achieved.
Index Description According to the Index Provider
  • The NYSE® Arca Biotechnology Index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
  • Such processes include, but are not limited to, recombinant DNA technology, molecular biology, genetic engineering, monoclonal antibody-based technology, lipid/liposome technology, and genomics.
  • The index is rebalanced quarterly based upon closing prices on the third Friday in January, April, July & October to ensure that each component stock continues to represent an approximately equal weight in the index.
Fund Overview
Fund TypeBiotechnology
Investment AdvisorFirst Trust Advisors L.P.
Investor Servicing AgentBank of New York Mellon Corp
Fiscal Year-End12/31
ExchangeNYSE Arca
Inception Price$20.00
Inception NAV$20.00
Rebalance FrequencyQuarterly
Gross Expense Ratio*0.55%
Net Expense Ratio*0.55%
* As of 5/2/2022
Expenses are capped contractually at 0.60% per year, at least through April 30, 2023. The Investment Advisor has implemented fee breakpoints, which reduce the fund's investment management fee at certain assets levels. Please see the fund's SAI for full details.
Current Fund Data (as of 2/3/2023)
Closing NAV1$163.74
Closing Market Price2$163.80
Bid/Ask Midpoint$163.82
Bid/Ask Premium0.05%
30-Day Median Bid/Ask Spread30.23%
Total Net Assets$1,563,736,027
Outstanding Shares9,550,002
Daily Volume27,022
Average 30-Day Daily Volume48,836
Closing Market Price 52-Week High/Low$165.37 / $123.32
Closing NAV 52-Week High/Low$165.07 / $123.39
Number of Holdings (excluding cash)30
NAV History (Since Inception)
Past performance is not indicative of future results.
Fund Characteristics (as of 1/31/2023)4
Maximum Market Cap.$134,675
Median Market Cap.$15,723
Minimum Market Cap.$1,620
Top Holdings (as of 2/3/2023)*
Holding Percent
FibroGen, Inc. 4.04%
Regeneron Pharmaceuticals, Inc. 3.57%
Ultragenyx Pharmaceutical Inc. 3.55%
Agios Pharmaceuticals, Inc. 3.53%
IQVIA Holdings Inc. 3.49%
Grifols, S.A. (ADR) 3.47%
Exelixis, Inc. 3.45%
Illumina, Inc. 3.45%
Seagen Inc. 3.45%
Charles River Laboratories International, Inc. 3.39%

* Excluding cash.  Holdings are subject to change.

Bid/Ask Premium/Discount (as of 2/3/2023)
  2022 Q1 2023 Q2 2023 Q3 2023
Days Traded at Premium 93 8 --- ---
Days Traded at Discount 158 15 --- ---
Hypothetical Growth of $10,000 Since Inception (as of 2/2/2023) *